Spherix Global Insights Reports Persistent High Unmet Need in Europe’s Evolving MASH Market
Three-quarters of gastroenterologists and hepatologists report high unmet need for MASH therapies, while access to approved treatments remains limited. EXTON, PA, July 8, 2026 — The European market for metabolic dysfunction-associated steatohepatitis (MASH) is entering a pivotal phase of development as increasing disease recognition converges with the recent approvals of Madrigal’s Rezdiffra (resmetirom) and Novo […]
Physicians and Patients Agree Lupus Care Is Improving, But Both Say Meaningful Gaps Remain
Parallel Spherix Global Insights studies reveal expanding biologic use and evolving treatment strategies have yet to fully translate into durable disease control and improved quality of life for many patients. EXTON, PA, July 7, 2026 — While the treatment landscape for systemic lupus erythematosus (SLE) continues to evolve with increasing biologic adoption and a growing […]
Novo’s success with oral Wegovy has been fueled by ‘familiarity’: Spherix
Originally published in Fierce Pharma Based on feedback from doctors, Novo Nordisk’s early success with the Wegovy pill may have been fueled in part by familiarity in the market with the GLP-1 compound. (Novo Nordisk) What’s been Novo Nordisk’s secret weapon to turn the tables on Eli Lilly and win the current market battle over […]
CTD-ILD Enters New Treatment Era, but Physicians Still See Significant Unmet Need
Only 15% of CTD-ILD patients achieve drug-free remission, fueling interest in Bristol Myers Squibb’s zola-cel, GSK’s Benlysta, and next-generation antifibrotics. EXTON, PA – June 17, 2026 – Despite the introduction of new therapies, connective tissue disease-associated interstitial lung disease (CTD-ILD) remains an area of significant unmet need, according to findings from the recently updated Special […]
Wayrilz (rilzabrutinib, Sanofi) Positioned to Define Third-Line Treatment in Warm Autoimmune Hemolytic Anemia (w-AIHA) as IMAAVY (niopcalimab, Jonhson & Johnson) Follows Closely with Positive Data Announcement at EHA 2026
New Spherix Global Insights research finds no clear standard of care beyond second line, creating an opportunity for novel therapies to establish themselves in refractory disease and potentially move earlier in treatment over time. EXTON, PA, June 12, 2026 — Despite widespread recognition that long-term steroid exposure should be minimized in patients with warm autoimmune […]
Brepocitinib Interest Gains Momentum in Idiopathic Inflammatory Myopathies as Rheumatologists Signal Readiness for Targeted, Steroid-Sparing Therapies
Spherix Global Insights highlights rising enthusiasm for Priovant’s TYK2/JAK1 inhibitor alongside continued dissatisfaction with current treatment approaches in dermatomyositis and polymyositis. EXTON, PA — May 28, 2026 — Spherix Global Insights has released the 2026 update of Market Dynamix™: Idiopathic Inflammatory Myopathies (IIM), US, revealing a market increasingly poised for disruption as rheumatologists seek more […]
Eli Lilly’s Oral GLP-1 Foundation Trails Novo Nordisk’s Wegovy Pill in Early Obesity Launch Uptake, According to Spherix Global Insights
Despite a more flexible administration profile, Foundayo generated lower first-month prescribing rates than the Wegovy Pill among both primary care physicians (PCPs) and endocrinologists. EXTON, PA, May 27, 2026 — As the obesity treatment landscape rapidly evolves, newly launched oral GLP-1 based treatments are introducing alternate treatment options for patients hesitant to initiate injectable weight […]
Rebalancing Agents Hympavzi (Pfizer), Qfitlia (Sanofi), Alhemo (Novo Nordisk) Gain Ground in Hemophilia as Physicians Navigate Access Barriers and Expanding Treatment Complexity
On World Hemophilia Day 2026, Spherix Global Insights announces the publication of data revealing early but evolving uptake across novel agents, with growing demand for deeper patient-level insights as treatment pathways diversify EXTON, PA — April 17, 2026 — New data from Spherix Global Insights’ Launch Dynamix™ service indicate that rebalancing agents are continuing to […]
PK Activation Gains Momentum in Thalassemia Agios’ Aqvesme Launch Reflects Strong Promise with Deliberate Uptake
With physicians identifying up to one-third of patients as candidates, early adoption reflects strong enthusiasm tempered by cautious real-world uptake. Exton, PA – March 31, 2026 – Spherix Global Insights today announced new findings from Launch Dynamix™: Aqvesme in Thalassemia, highlighting early physician perceptions and adoption dynamics of Agios’ Aqvesme and its initial integration into […]
CAR T-cell therapy moving to frontline as myeloma treatment
Originally published in BioNews Report says most doctors see therapies becoming standard 1st-line treatment Most doctors who treat multiple myeloma expect that CAR T-cell therapies will soon became the standard first-line treatment, according to new research from market analytics company Spherix Global Insights. The trend marks a shift in attitudes among myeloma experts. Last year, doctors tended to report more […]